Cost-Effectiveness of Pantoprazole to Prevent Upper Gastrointestinal Bleeding in Mechanically Ventilated Patients
Files
(Published version)
Date
2025
Authors
Xie, F.
Yao, Y.
Ma, Y.
Humphries, B.
Lau, V.I.
Fowler, R.
Rochwerg, B.
Heels-Ansdell, D.
Zytaruk, N.
Barletta, J.F.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
JAMA Network Open, 2025; 8(12):e2552771-1-e2552771-12
Statement of Responsibility
Feng Xie, Yifan Yao, Yue Ma, Brittany Humphries, Vincent I. Lau, Robert Fowler, Bram Rochwerg, Diane Heels-Ansdell, Nicole Zytaruk, Jeffrey F. Barletta, Salmaan Kanji, Yaseen M. Arabi, Daniel W. Johnson, David Williamson, John C. Marshall, Adam Deane, John Myburgh, Anna Geagea, Alex Poole, Patrick Archambault, Kosar Khwaja, Marlies Ostermann, Lisa Burry, Gordon H. Guyatt, Deborah J. Cook, for the E-REVISE Collaborators and the Canadian Critical Care Trials Group
Conference Name
Abstract
IMPORTANCE Pantoprazole reduces clinically important upper gastrointestinal bleeding in critically ill patients. However, the cost-effectiveness of this strategy is unclear. OBJECTIVE To assess the cost-effectiveness of daily intravenous pantoprazole vs no pantoprazole for preventing upper gastrointestinal bleeding in mechanically ventilated patients. DESIGN, SETTING, AND PARTICIPANTS This prospective health economic evaluation was conducted alongside the Reevaluating the Inhibition of Stress Erosions (REVISE) trial over a time horizon of intensive care unit (ICU) admission to hospital discharge or death from a public health care payer’s perspective. The REVISE trial included critically ill adults from Canada, Australia, the US, England, Saudi Arabia, Brazil, Kuwait, and Pakistan receiving invasive ventilation. INTERVENTIONS Daily intravenous pantoprazole (40mg) or placebo (0.9%sodium chloride). MAIN OUTCOMES AND MEASURES The primary outcome was the incremental cost per clinically important upper gastrointestinal bleed prevented. The base-case analysis included all study site– specific resource utilization. Canadian costs were applied to measured resource uses across sites. Sensitivity analyses were conducted across cost ranges and using US-based cost estimates. Uncertainty was assessed using nonparametric bootstrapping simulations. All costs are presented in 2025 US dollars. RESULTS 4821 invasively ventilated critically ill patients (mean [SD] age, 58.2 [16.4] years; 1752 female [36.3%]) were enrolled from 68 ICUs. For pantoprazole, the mean (SD) stay was 12.4 (11.7) days in the ICU and an additional 14.8 (28.0) days in the hospital, as compared with 13.3 (13.3) days in the ICU and 16.5 (42.9) days in the hospital for no pantoprazole. Mean (SD) total per-patient costs were $60 466 ($58 546) for pantoprazole vs $65 423 ($75 661) for no pantoprazole. The incremental cost per patient was −$4957 (95%CI, −$8777 to −$1136). In a sensitivity analysis, US costs were applied for pantoprazole, bleeding, and ICU and hospital stay to all patients; mean (SD) total per-patient costs were $130 179 ($123 456) for pantoprazole vs $140 770 ($153 195) for no pantoprazole (incremental cost: −$10 591; 95%CI, −$18 448 to $−2735). When excluding top 10% of patients in terms of ICU days,ward days, and total costs, the incremental costswere −$1151, −$3388, and −$1356, respectively. In 99% of simulations, the strategy of using pantoprazole was more effective and less costly than no pantoprazole.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2025 Xie F et al. This is an open access article distributed under the terms of the CC-BY License.